Puma Biotechnology (PBYI) to Release Quarterly Earnings on Thursday

Puma Biotechnology (NASDAQ:PBYI) is scheduled to be issuing its quarterly earnings data after the market closes on Thursday, May 2nd. Analysts expect the company to announce earnings of ($0.16) per share for the quarter. Puma Biotechnology has set its Q1 2024 guidance at EPS and its FY 2024 guidance at EPS.Parties that wish to listen to the company’s conference call can do so using this link.

Puma Biotechnology (NASDAQ:PBYI) last announced its earnings results on Thursday, February 29th. The biopharmaceutical company reported $0.26 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.07). Puma Biotechnology had a net margin of 9.16% and a return on equity of 58.21%. The business had revenue of $72.20 million for the quarter, compared to the consensus estimate of $73.22 million. On average, analysts expect Puma Biotechnology to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Puma Biotechnology Price Performance

Shares of NASDAQ:PBYI opened at $4.83 on Thursday. The business has a 50 day moving average price of $5.64 and a 200 day moving average price of $4.55. Puma Biotechnology has a twelve month low of $2.13 and a twelve month high of $7.73. The company has a market cap of $232.84 million, a price-to-earnings ratio of 10.50, a PEG ratio of 2.94 and a beta of 1.28. The company has a quick ratio of 1.50, a current ratio of 1.57 and a debt-to-equity ratio of 1.23.

Analyst Upgrades and Downgrades

PBYI has been the subject of several recent research reports. StockNews.com cut Puma Biotechnology from a “buy” rating to a “hold” rating in a report on Wednesday, April 10th. HC Wainwright cut their price target on Puma Biotechnology from $8.00 to $7.00 and set a “buy” rating for the company in a report on Friday, March 1st.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.